Project
A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents
Ongoing - recruitment active · 2023 until 2028
Fischer Stefanie, Harder Anja, Quinter Janine
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2023
End Date
2028
Financing
Others
Labels
prostate cancer